Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
-7.51 (-2.51%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 290.88 - 298.50
52 week 244.28 - 370.57
Open 297.75
Vol / Avg. 0.00/1.61M
Mkt cap 61.75B
P/E 16.71
Div/yield     -
EPS 17.46
Shares 211.56M
Beta 0.75
Inst. own 92%
Apr 23, 2018
Q1 2018 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 14, 2018
Biogen Inc at Leerink Partners Global Healthcare Conference - Webcast
Jan 25, 2018
Q4 2017 Biogen Inc Earnings Release
Jan 25, 2018
Q4 2017 Biogen Inc Earnings Call - Webcast
Jan 8, 2018
Biogen Inc at JPMorgan Healthcare Conference - Webcast
Dec 13, 2017
Biogen Inc at Guggenheim Boston Healthcare Conference - Webcast
Nov 29, 2017
Biogen Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 30.46% 31.32%
Operating margin 44.32% 43.54%
EBITD margin - 54.25%
Return on average assets 17.29% 16.52%
Return on average equity 27.59% 30.00%
Employees 7,300 -
CDP Score - B


225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Michel Vounatsos Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey D. Capello Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Ginger Gregory Ph.D. Chief Human Resource Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michael D. Ehlers M.D., Ph.D. Executive Vice President, Head - Research and Development
Age: 48
Bio & Compensation  - Reuters
Chirfi Guindo Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 54
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Executive Vice President, President - International and Head of Global Therapeutic Operations
Age: 51
Bio & Compensation  - Reuters